The evolution of parkinsonism in primary progressive apraxia of speech: A 6-year longitudinal study.


Journal

Parkinsonism & related disorders
ISSN: 1873-5126
Titre abrégé: Parkinsonism Relat Disord
Pays: England
ID NLM: 9513583

Informations de publication

Date de publication:
12 2020
Historique:
received: 09 04 2020
revised: 11 09 2020
accepted: 27 09 2020
pubmed: 13 10 2020
medline: 30 10 2021
entrez: 12 10 2020
Statut: ppublish

Résumé

Primary progressive apraxia of speech (PPAOS) is a neurodegenerative syndrome in which patients present with an isolated motor speech disorder. Some PPAOS patients develop parkinsonism and other features of progressive supranuclear palsy (PSP) and/or corticobasal syndrome (CBS) over time. We aimed to assess the evolution of parkinsonian characteristics in PPAOS patients who had been followed yearly for at least six years. From a large cohort of 46 PPAOS patients, eight were followed yearly for > 6-years in multiple NIH-funded grants. Parkinsonian and other features, including bradykinesia, tremor, rigidity, postural instability, apraxia, ocular motor function and cognition were assessed at each visit, and research criteria applied for PSP and CBS diagnosis. Neurological, speech-language test scores, and [ A Parkinson's plus syndrome developed in all eight patients (100%). Bradykinesia was the earliest feature, followed by rigidity and postural instability. Tremor was not a significant feature. Parkinsonism, limb apraxia and ocular motor impairment tended to develop four-to-five years after onset with some patients having slight asymmetric parkinsonism. Six patients (75%) met research criteria for probable PSP, although only one for PSP-Richardson's syndrome; three patients met criteria for possible CBS. Slightly asymmetric, left-sided, hypometabolism was observed on FDG-PET, not matching asymmetry of Parkinsonism. Midbrain hypometabolism was absent-minimal. Three patients had progressive midbrain volumes in the PSP-Richardson's syndrome range. A Parkinson's plus syndrome may inevitably develop in PPAOS supporting PPAOS as an early presentation of a Parkinson's plus disorder.

Identifiants

pubmed: 33045651
pii: S1353-8020(20)30771-9
doi: 10.1016/j.parkreldis.2020.09.039
pmc: PMC7769910
mid: NIHMS1636641
pii:
doi:

Substances chimiques

Radiopharmaceuticals 0
Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

34-40

Subventions

Organisme : NIDCD NIH HHS
ID : R01 DC010367
Pays : United States
Organisme : NIDCD NIH HHS
ID : R01 DC012519
Pays : United States
Organisme : NIDCD NIH HHS
ID : R01 DC014942
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS089757
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Références

J Int Neuropsychol Soc. 2017 Sep;23(8):675-684
pubmed: 28716165
Am J Speech Lang Pathol. 2018 Nov 21;27(4):1303-1318
pubmed: 30458509
Neurology. 2013 Jan 29;80(5):496-503
pubmed: 23359374
Neurology. 2000 Dec 12;55(11):1621-6
pubmed: 11113214
Eur J Neurol. 2012 Nov;19(11):1440-6
pubmed: 22519566
Brain. 2006 Jun;129(Pt 6):1385-98
pubmed: 16613895
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
J Neurol. 2015 Sep;262(9):2064-72
pubmed: 26076744
Brain. 2012 May;135(Pt 5):1522-36
pubmed: 22382356
Neurocase. 2018 Apr;24(2):111-120
pubmed: 29799310
Adv Neurol. 2000;82:103-21
pubmed: 10624475
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
Mov Disord Clin Pract. 2019 May 29;6(6):452-461
pubmed: 31392246
Arch Neurol. 2011 Jun;68(6):753-60
pubmed: 21670399
Brain. 2007 Jun;130(Pt 6):1552-65
pubmed: 17405767
Brain. 2019 Aug 1;142(8):2466-2482
pubmed: 31199471
Neurology. 2013 Jul 23;81(4):337-45
pubmed: 23803320
Eur J Neurol. 2013 Apr;20(4):629-37
pubmed: 23078273
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
J Nucl Med. 1995 Jul;36(7):1238-48
pubmed: 7790950
J Neurol Neurosurg Psychiatry. 1998 Feb;64(2):184-9
pubmed: 9489528
Brain. 2014 Oct;137(Pt 10):2783-95
pubmed: 25113789
J Neurol Neurosurg Psychiatry. 1992 Jul;55(7):577-80
pubmed: 1640234
Mov Disord. 2019 Aug;34(8):1228-1232
pubmed: 30884545
J Neuropsychiatry Clin Neurosci. 2000 Spring;12(2):233-9
pubmed: 11001602

Auteurs

Zeynep Idil Seckin (ZI)

Department of Neurology, Movement Disorders, Mayo Clinic, Rochester, MN, USA.

Joseph R Duffy (JR)

Department of Neurology, Speech Pathology, Mayo Clinic, Rochester, MN, USA.

Edythe A Strand (EA)

Department of Neurology, Speech Pathology, Mayo Clinic, Rochester, MN, USA.

Heather M Clark (HM)

Department of Neurology, Speech Pathology, Mayo Clinic, Rochester, MN, USA.

Rene L Utianski (RL)

Department of Neurology, Speech Pathology, Mayo Clinic, Rochester, MN, USA.

Mary M Machulda (MM)

Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.

Hugo Botha (H)

Department of Neurology, Behavioral Neurology, Mayo Clinic, Rochester, MN, USA.

Farwa Ali (F)

Department of Neurology, Movement Disorders, Mayo Clinic, Rochester, MN, USA.

Nha Trang Thu Pham (NT)

Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA; Department of Radiology, Mayo Clinic, Rochester, MN, USA.

Val J Lowe (VJ)

Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA; Department of Radiology, Mayo Clinic, Rochester, MN, USA.

Jennifer L Whitwell (JL)

Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA; Department of Radiology, Mayo Clinic, Rochester, MN, USA.

Keith A Josephs (KA)

Department of Neurology, Movement Disorders, Mayo Clinic, Rochester, MN, USA; Department of Neurology, Behavioral Neurology, Mayo Clinic, Rochester, MN, USA. Electronic address: josephs.keith@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH